Donor-Derived Cell-Free DNA for Acute Rejection Monitoring in Heart and Lung Transplantation.

Existing evidence shows that dd-cfDNA is a safe, convenient, and reliable method of acute rejection monitoring in heart and lung transplant recipients. Further studies are required to validate threshold values for clinical use and determine its role in the diagnosis of alternative forms of allograft injury.